Erlotinib-induced florid acneiform rash complicated by extensive impetiginization

Clinical and Experimental Dermatology

Volumn 33, Issue 1, 2008, Pages 46-49

  Kardaun, S H ^a   Van Duinen, K F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CASTOR OIL; EAR DROPS; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EYE DROPS; HYDROXYZINE; KETOCONAZOLE; MINOCYCLINE; SALICYLIC ACID; SULFADIAZINE SILVER; TRIAMCINOLONE; ZINC;

ACNE; ADULT; AGED; ARM; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; CAUCASIAN; CREAM; DIARRHEA; DISEASE EXACERBATION; DRUG ERUPTION; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; ERYTHEMATOSQUAMOUS SKIN DISEASE; EVENING DOSAGE; FACE; HUMAN; IMPETIGO; LEG; LOBECTOMY; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; PRIORITY JOURNAL; PRURITUS; PUSTULE; SLEEP DISORDER;

AGED; ANTI-BACTERIAL AGENTS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; EMOLLIENTS; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; PROTEIN KINASE INHIBITORS; PRURITUS; QUINAZOLINES;

EID: 37349121157     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2007.02556.x     Document Type: Article

References (10)

1. Pérez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004 22 : 3238 47.
2. Pérez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol 2005 23 : 5235 46.
3. Mascio F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003 163 : 303 12.
4. Tang PA, Tsao M, Moore MJ. A review of erlotinib and its clinical use. Expert Opin Pharmacother 2006 7 : 177 93.
5. Hidalgo M, Siu LL, Nemunaitis J et al. Phase I pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001 19 : 3267 79.
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 353 : 123 32.
7. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005 16 : 1425 33.
8. Busam KJ, Capodieci P, Motzer R et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001 144 : 1169 76.
9. Jacot W, Bessis D, Jorda E et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004 151 : 238 41.
10. Shah NT, Kris MG, Pao W et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005 23 : 165 74.